GLPwatch
Byetta for Anxiety
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCByetta (exenatide) is not FDA-approved for anxiety, and any use for this condition is off-label or investigational. Studies in mice suggest exenatide may reduce anxiety-like behavior in certain conditions, such as sleep deprivation, diabetes, obesity, or inflammation models, but these findings have not been confirmed in humans.
AI summary of the sources below.
| Drug | Byetta (exenatide) |
|---|---|
| Condition | Anxiety |
| Approval status | Investigational / off-label |
| Research papers | 4 |
Byetta is not FDA-approved for anxiety; the research below reflects investigational or off-label study only.
Research on exenatide for anxiety (4)
- The effects of glucagon-like peptide 1 receptor agonist (exenatide) on memory impairment, and anxiety- and depression-like behavior induced by REM sleep deprivation.
- Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes.
- The GLP-1 receptor agonist exenatide ameliorates neuroinflammation, locomotor activity, and anxiety-like behavior in mice with diet-induced obesity through the modulation of microglial M2 polarization and downregulation of SR-A4.
- Exenatide, a GLP-1 analog, has healing effects on LPS-induced autism model: Inflammation, oxidative stress, gliosis, cerebral GABA, and serotonin interactions.